​
​

LENZ Therapeutics (GRPH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

GRPH Stock Forecast

LENZ Therapeutics stock forecast is as follows: an average price target of $4.00 (represents a -82.03% downside from GRPH’s last price of $22.26) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.

GRPH Price Target

The average price target for LENZ Therapeutics (GRPH) is $4.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $2.00. This represents a potential -82.03% downside from GRPH's last price of $22.26.

GRPH Analyst Ratings

Hold

According to 4 Wall Street analysts, LENZ Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for GRPH stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 4 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

LENZ Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 03, 2023-Morgan Stanley$3.00$2.1837.61%-86.52%
Jan 06, 2023-RBC Capital$4.00$3.0630.72%-82.03%
Jan 06, 2023-Leerink Partners$2.00$3.06-34.64%-91.02%
Jan 06, 2023-BMO Capital$7.00$3.06128.76%-68.55%
Jul 15, 2022-Morgan Stanley$6.00$3.3081.82%-73.05%
Row per page
Go to

The latest LENZ Therapeutics stock forecast, released on Feb 03, 2023 by Morgan Stanley company, set a price target of $3.00, which represents a 37.61% increase from the stock price at the time of the forecast ($2.18), and a -86.52% decrease from GRPH last price ($22.26).

LENZ Therapeutics Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$22.26$22.26$22.26
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of LENZ Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to LENZ Therapeutics's last price of $22.26. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Feb 03, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Jan 06, 2023RBC CapitalSector PerformSector PerformHold
Jan 06, 2023SVB Leerink-Market PerformDowngrade
Jan 06, 2023BMO CapitalOutperformMarket PerformDowngrade
Jul 15, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jun 17, 2022BMO Capital-OutperformInitialise
Feb 18, 2022RBC Capital-Sector PerformInitialise
Row per page
Go to

LENZ Therapeutics's last stock rating was published by Morgan Stanley on Feb 03, 2023. The company gave GRPH a "Equal-Weight" rating, the same as its previous rate.

LENZ Therapeutics Financial Forecast

LENZ Therapeutics Revenue Forecast

Dec 24Oct 24Jul 24Mar 24
Revenue----
Avg Forecast----
High Forecast----
Low Forecast----
# Analysts----
Surprise %----

LENZ Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GRPH's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

LENZ Therapeutics EBITDA Forecast

Dec 24Oct 24Jul 24Mar 24
# Analysts----
EBITDA----
Avg Forecast----
High Forecast----
Low Forecast----
Surprise %----

undefined analysts predict GRPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than LENZ Therapeutics's previous annual EBITDA (undefined) of $NaN.

LENZ Therapeutics Net Income Forecast

Dec 24Oct 24Jul 24Mar 24
# Analysts----
Net Income----
Avg Forecast$-424.58K$-424.58K$-471.76K$-518.94K
High Forecast$-424.58K$-424.58K$-471.76K$-518.94K
Low Forecast$-424.58K$-424.58K$-471.76K$-518.94K
Surprise %----

LENZ Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GRPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

LENZ Therapeutics SG&A Forecast

Dec 24Oct 24Jul 24Mar 24
# Analysts----
SG&A----
Avg Forecast----
High Forecast----
Low Forecast----
Surprise %----

LENZ Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GRPH last annual SG&A of $NaN (undefined).

LENZ Therapeutics EPS Forecast

Dec 24Oct 24Jul 24Mar 24
# Analysts----
EPS----
Avg Forecast$-0.09$-0.09$-0.10$-0.11
High Forecast$-0.09$-0.09$-0.10$-0.11
Low Forecast$-0.09$-0.09$-0.10$-0.11
Surprise %----

According to undefined Wall Street analysts, LENZ Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GRPH previous annual EPS of $NaN (undefined).

LENZ Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SNSESensei Biotherapeutics$0.45$5.501122.22%Buy
CTMXCytomX Therapeutics$0.91$5.73529.67%Buy
TILInstil Bio$26.50$78.25195.28%Hold
NUVBNuvation Bio$2.63$6.75156.65%Buy
NXTCNextCure$1.31$3.00129.01%Buy
ASMBAssembly Biosciences$16.14$35.50119.95%Buy
ACHLAchilles Therapeutics$1.05$2.0090.48%Buy
GRPHLENZ Therapeutics$3.18$4.0025.79%Hold

GRPH Forecast FAQ

Is LENZ Therapeutics a good buy?

No, according to 4 Wall Street analysts, LENZ Therapeutics (GRPH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of GRPH's total ratings.

What is GRPH's price target?

LENZ Therapeutics (GRPH) average price target is $4 with a range of $2 to $7, implying a -82.03% from its last price of $22.26. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will LENZ Therapeutics stock go up soon?

According to Wall Street analysts' prediction for GRPH stock, the company can go down by -82.03% (from the last price of $22.26 to the average price target of $4), down by -68.55% based on the highest stock price target, and down by -91.02% based on the lowest stock price target.

Can LENZ Therapeutics stock reach $30?

GRPH's average twelve months analyst stock price target of $4 does not support the claim that LENZ Therapeutics can reach $30 in the near future.

What are LENZ Therapeutics's analysts' financial forecasts?

GRPH's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-1.84M (high $-1.84M, low $-1.84M), average SG&A $0 (high $0, low $0), and average EPS is $-0.39 (high $-0.39, low $-0.39).